| Efficacy and Safety of Pregabalin in Neuropathic Pain Followed Spinal Cord Injury A Review and Meta-Analysis of Randomized Controlled Trials | |
| Yu, Xiaobing1,2,3; Liu, Tao1; Zhao, Dewei1,2; Yang, Ke3; Zhang, Xiuzhi1; Zhang, Meng1; Zhang, Shuo1; Huang, Wei1; Wu, Baolin1; Li, Junlei1 | |
| Corresponding Author | Yu, Xiaobing(dldxyxb@163.com) |
| 2019-03-01 | |
| Source Publication | CLINICAL JOURNAL OF PAIN
 |
| ISSN | 0749-8047 |
| Volume | 35Issue:3Pages:272-278 |
| Abstract | Objective: Pregabalin has been approved for the treatment of the neuropathic pain following spinal cord injury (SCI). We performed a systemic review and meta-analysis of randomized, controlled, multicenter trials to evaluate the efficacy and safety of pregabalin for SCI-induced neuropathic pain. Materials and Methods: Research searching was performed in PubMed and EMBASE databases and the Cochrane library in May 2018. Clinical controlled trials using pregabalin for the pain treatment following SCI in adults (18 y old and above) were included. Pain and safety-related adverse events were considered as outcomes. Meta-analysis was conducted using Revman 5.0 software. Results: Five publications (pregabalin, patients=261, placebo, patients=216) were included in our study. After at least 4-week's treatment with pregabalin (flexible dose, 150 to 600 mg/d), pregabalin-treated patients showed reduced pain -1.54, 95% confidence interval (CI) (-2.33, -0.75), P=0.0001; improved >30% 1.83, 95% CI (1.37, 2.46), P50% pain relief 2.40, 95% CI (1.53, 3.77), P=0.0001; increased adverse events 1.36, 95% CI (1.18, 1.577), P<0.0001; and reduced Hospital Anxiety and Depression Scale - anxiety -1.50, 95% CI (-2.99, -0.00), P=0.05 and - depression -0.34, 95% CI (-0.55, -0.12), P=0.002 scores compared with placebo-treated patients. Stratified meta-analysis showed there was no difference in primary adverse events (drowsiness, dizziness, peripheral edema, and dry mouth) between pregabalin and placebo groups (P >= 0.05). Conclusions: Our results showed pregabalin was efficacious and might be safe treatment for chronic pain followed SCI. |
| Keyword | pregabalin neuropathic pain spinal cord injury efficacy mata-analysis |
| DOI | 10.1097/AJP.0000000000000675 |
| Indexed By | SCI |
| Language | 英语 |
| WOS Research Area | Anesthesiology ; Neurosciences & Neurology |
| WOS Subject | Anesthesiology ; Clinical Neurology |
| WOS ID | WOS:000459157400009 |
| Publisher | LIPPINCOTT WILLIAMS & WILKINS |
| Citation statistics | |
| Document Type | 期刊论文 |
| Identifier | http://ir.imr.ac.cn/handle/321006/131947 |
| Collection | 中国科学院金属研究所 |
| Corresponding Author | Yu, Xiaobing |
| Affiliation | 1.Dalian Univ, Zhongshan Hosp, Dept Orthopaed, Dalian, Peoples R China 2.Dalian Univ, Zhongshan Hosp, Postdoctoral Workstn, Dalian, Peoples R China 3.Chinese Acad Sci, Inst Met Res, Shenyang, Liaoning, Peoples R China |
| Recommended Citation GB/T 7714 | Yu, Xiaobing,Liu, Tao,Zhao, Dewei,et al. Efficacy and Safety of Pregabalin in Neuropathic Pain Followed Spinal Cord Injury A Review and Meta-Analysis of Randomized Controlled Trials[J]. CLINICAL JOURNAL OF PAIN,2019,35(3):272-278. |
| APA | Yu, Xiaobing.,Liu, Tao.,Zhao, Dewei.,Yang, Ke.,Zhang, Xiuzhi.,...&Li, Junlei.(2019).Efficacy and Safety of Pregabalin in Neuropathic Pain Followed Spinal Cord Injury A Review and Meta-Analysis of Randomized Controlled Trials.CLINICAL JOURNAL OF PAIN,35(3),272-278. |
| MLA | Yu, Xiaobing,et al."Efficacy and Safety of Pregabalin in Neuropathic Pain Followed Spinal Cord Injury A Review and Meta-Analysis of Randomized Controlled Trials".CLINICAL JOURNAL OF PAIN 35.3(2019):272-278. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment